SL
Suzhou Lixin Pharmaceutical Co., Ltd.
CDMO · Suzhou, China
Overview
Suzhou Lixin Pharmaceutical has made APIs and intermediates since 2000, mainly in oncology, cardiovascular, antiviral and digestive areas, and offers CDMO and CMO services. Its site reports eight EDQM CEPs and an FDA first-generic approval for nilotinib in 2022, and says the related Shandong Lixin Pharmaceutical site passed an FDA cGMP inspection in 2023; that inspection was not of the Suzhou entity, so regulatorGmp is left false. The FDA DMF list shows an active Type II DMF for semaglutide.
Capabilities
- Semaglutide API
- Oncology and cardiovascular APIs
- Advanced intermediates
- CDMO/CMO services
Quality signals
| GMP evidence | Not found |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |